Skip to main content

Table 2 Life table displaying the cumulative probabilities of survival in the phaco/ECP, phaco/MP-TSCPC, and phaco alone groups at 100 and 200 days postoperatively. Failure was defined as reaching NLP vision at any point postoperatively, undergoing additional glaucoma surgery, or the inability to maintain ≥ 20% IOP reduction from baseline with IOP between 5–18 mmHg for two consecutive follow-up visits while maintaining ≤ baseline medications

From: Transscleral vs endoscopic cyclophotocoagulation: safety and efficacy when combined with phacoemulsification

 

Survival Probability

95% CI

Phaco/ECP

 100 ± 15 days

37.0%

(22.6%, 60.6%)

 200 ± 15 days

32.4%

(18.6%, 56.6%)

Phaco/MP-TSCPC

 100 ± 15 days

67.0%

(47.0%, 95.5%)

 200 ± 15 days

58.6%

(37.7%, 91.1%)

Phaco

 100 ± 15 days

18.8%

(5.4%, 65%)

 200 ± 15 days

0

N/A

  1. CI Confidence Interval, phaco phacoemulsification, MP-TSCPC Micropulse Transscleral Cyclophotocoagulation (IRIDEX Corp., Mountainview, CA), ECP Endoscopic cyclophotocoagulation